44. San Antonio Breast Cancer Symposium

Das 44. San Antonio Breast Cancer Symposium (SABCS) fand vom 7. bis 10. Dezember 2021 erstmals im Hybridformat statt. Im Fokus stand die Vorstellung von über 1000 Abstracts zur Prävention, Diagnose und Therapie von Brustkrebs.

Publikationsverlauf

Artikel online veröffentlicht:
24. Februar 2022

• Literatur

• 1 Cortes J. et al Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. SABCS. 2021 Abstract GS1-02
• 2 Coombes C. et al Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer. SABCS. 2021 Abstract GS3-10.
• 3 Xu B. et al Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22 (03) 351-360 DOI: 10.1016/S1470-2045(20)30702-6.
• 4 Xu B. et al Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer. SABCS. 2021 Abstract GS3-02
• 5 Bidard FC. et al Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR + HER2-metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial. SABCS. 2021 Abstract GS3-05
• 6 Goodwin PJ. et al CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin vs placebo in early breast cancer: results of the primary efficacy analysis SABCS. 2021 Abstract GS1-08